Does race influence health-related quality of life and toxicity following proton therapy for prostate cancer?

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 39, Issue 3, 2016, Pages 261-265

  Bryant, Curtis ^a   Mendenhall, Nancy P ^a   Henderson, Randal H ^a   Nichols, Romaine C ^a   Mendenhall, William M ^a   Morris, Christopher G ^a   Williams, Christopher ^a   Su, Zhong ^a   Li, Zuofeng ^a   Hoppe, Bradford S ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Particle therapy; Proton therapy; Quality of life; Race; Toxicity

Indexed keywords

DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; CYSTITIS; ERECTILE DYSFUNCTION; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HEMATURIA; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE SIZE; PROTON THERAPY; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; RECTUM HEMORRHAGE; SEMINAL VESICLE; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT OBSTRUCTION; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; ADVERSE EFFECTS; AFRICAN AMERICAN; BLADDER OBSTRUCTION; BLOOD; CAUCASIAN; COMPLICATION; ETHNOLOGY; MIDDLE AGED; PROSTATIC NEOPLASMS; QUESTIONNAIRE; SEXUALITY;

AFRICAN AMERICANS; AGED; ANDROGEN ANTAGONISTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTON THERAPY; QUALITY OF LIFE; SEXUALITY; SURVEYS AND QUESTIONNAIRES; URINARY BLADDER NECK OBSTRUCTION; URINARY INCONTINENCE;

EID: 84897364332     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000050     Document Type: Article

References (22)

1. Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003;21:3979-3986.
2. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250-1261.
3. Catalona WJ, Carvalhal GF, Mager DE, et al. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol. 1999;162:433-438.
4. Eastham JA, Kattan MW, Rogers E, et al. Risk factors for urinary incontinence after radical prostatectomy. J Urol. 1996;156:1707-1713.
5. Penedo FJ, Dahn JR, Shen BJ, et al. Ethnicity and determinants of quality of life after prostate cancer treatment. Urology. 2006;67:1022-1027.
6. Rice K, Hudak J, Peay K, et al. Comprehensive quality-of-life outcomes in the setting of a multidisciplinary, equal access prostate cancer clinic. Urology. 2010;76:1231-1238.
7. Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011;306:1205-1214.
8. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000;283:354-360.
9. Powell IJ, Banerjee M, Novallo M, et al. Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease. Urology. 2000;55:246-251.
10. Yamoah K, Stone N, Stock R. Impact of race on biochemical disease recurrence after prostate brachytherapy. Cancer. 2011;117:5589-5600.
11. Winkfield KM, Chen MH, Dosoretz DE, et al. Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2011;81:e345-e350.
12. Barrett WL, Kassing WM, Shirazi R. Efficacy of brachytherapy for prostate cancer in African Americans compared with Caucasians. Brachytherapy. 2004;3:30-33.
13. Hoppe BS, Nichols RC, Henderson RH, et al. Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. Cancer. 2012;118:4619-4626.
14. Nichols RC Jr, Morris CG, Hoppe BS, et al. Proton radiotherapy for prostate cancer is not associated with post-treatment testosterone suppression. Int J Radiat Oncol Biol Phys. 2012;82: 1222-1226.
15. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol. 2010;28:1106-1111.
16. Mendenhall NP, Li Z, Hoppe BS, et al. Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:213-221.
17. Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307:1611-1620.
18. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990-1996.
19. Pollack A, Walker G, Horwitz EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013;31:3860-3868.
20. McGee L, Mendenhall NP, Henderson RH, et al. Outcomes in men with large prostates (> / = 60 cm(3)) treated with definitive proton therapy for prostate cancer. Acta Oncol. 2013;52: 470-476.
21. Shah C, Jones PM, Wallace M, et al. Differences in disease presentation, treatment outcomes, and toxicities in African American patients treated with radiation therapy for prostate cancer. Am J Clin Oncol. 2012;35:566-571.
22. Vargas C, Fryer A, Mahajan C, et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:744-751.